PHILADELPHIA & NASHVILLE, Tenn.–(BUSINESS WIRE)–Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and Sarah Cannon
Research Institute (Sarah Cannon) announced today a unique collaboration
to advance clinical research through an expanded early phase drug
development program and investigator initiated trials, leveraging the
strengths of each. The organizations will combine expertise in drug
development and research support services, which will expand the menu of
clinical trials to patients across the Delaware Valley and beyond.
Additionally, Sarah Cannon will provide SKCC-designed clinical trials in
sites within their national network.
“By combining the strengths of SKCC and Sarah Cannon’s robust cancer
programs, we are bringing together experts who share a mission to
advance cancer research so that patients will have greater access to the
latest treatment options that focus on personalized care,” said Karen E.
Knudsen, PhD, Director of the NCI-designated Sidney Kimmel Cancer Center
– Jefferson Health. “We are excited to form a strategic partnership that
will accelerate drug development both nationally and globally, with the
goal of impacting a larger population of patients seeking new therapies.”
Sidney Kimmel Cancer Center – Jefferson Health is one of only 70
NCI-Designated Centers in the United States. Thomas Jefferson University
Hospital, the academic medical center for the Sidney Kimmel Cancer
Center, recently ranked as a top 20 hospital by U.S. News & World
Report in 2017-2018 for cancer care. Led by Dr. Knudsen, SKCC has
distinguished itself nationally through practice-changing discoveries
which are rapidly implemented into clinical trials. At present,
approximately 20% of Sidney Kimmel Cancer Center patients take advantage
of advanced care options through clinical trials.
Sarah Cannon pioneered the first community-based drug development
program in the United States and has grown to become a global leader in
early phase research as well as in community-based cancer care. The
organization has conducted more than 300 first-in-human studies and has
been a clinical trial leader in the majority of approved cancer
therapies over the last decade. Through its network of research sites,
Sarah Cannon serves thousands of patients annually in clinical trials,
including through its drug development units in Nashville, Tenn.,
Sarasota, Fla., Denver, Colo., and London, England.
“At Sarah Cannon, we are focused on offering patients cutting-edge
cancer therapies closer to home – a commitment shared by our esteemed
colleagues at SKCC,” said Howard A. “Skip” Burris, III, MD, President
and Chief Medical Officer at Sarah Cannon. “Together, this collaboration
will make a greater impact on the field of cancer research through the
synergy of our scientific and operational expertise.”
In addition to the collaboration in clinical research, SKCC and Sarah
Cannon will work together to advance blood cancer care through Sarah
Cannon’s Blood Cancer Network (BCN). The BCN is comprised of individual
programs that have long been recognized as leaders in blood cancer
patient care and outcomes. By joining Sarah Cannon’s network, programs
such as SKCC are committed to delivering the highest level of quality
standards, infrastructure, training and research to provide an
unparalleled experience for patients seeking blood cancer treatment.
Sarah Cannon is also one of the world’s largest providers of
hematopoietic cell transplantation (HCT), performing more than 1,000
transplants per year.
Jefferson Health, home of Sidney Kimmel Medical College, is reimagining
health care in the greater Philadelphia region and southern New Jersey.
Jefferson’s dedicated team of doctors, nurses, health professionals and
staff provides a range of primary to highly-specialized care through 14
hospitals (three Magnet®-designated for nursing excellence), more than
50 outpatient and urgent care locations, the NCI-designated Sidney
Kimmel Cancer Center, Magee Rehabilitation and the JeffConnect®
telemedicine program. Jefferson’s academic health center, Thomas
Jefferson University Hospitals, Inc., is recognized by US News & World
Report as #16 on the 2017-18 Best Hospitals Honor Roll. Jefferson
Health’s mission is to improve the health of those patients and
communities it is privileged to serve through safe, effective,
equitable, compassionate care.
Sarah Cannon Research Institute is the research arm of HCA Healthcare’s
global cancer institute, Sarah Cannon. Focused on advancing therapies
for patients, it is one of the world’s leading clinical research
organizations conducting community-based clinical trials throughout the
United States and United Kingdom. Sarah Cannon’s network of strategic
sites includes more than 275 physicians who engage in research. The
organization has led more than 300 first-in-man clinical trials since
its inception in 1993, and has been a clinical trial leader in the
majority of approved cancer therapies over the last 10 years.
Additionally, Sarah Cannon offers management, regulatory, and other
research support services for drug development and industry sponsors as
well as strategic investigator sites through its contract research
organization (CRO), Sarah Cannon Development Innovations. For more
information, visit sarahcannon.com.